The Evolving Role of Disulfiram in Radiobiology and the Treatment of Breast Cancer
| Autor: | Peishun Wang, Rui Wang, Jun Shen, Tianfu Dong, Huanhuan Yan, Xitao Gao, Jun Zhou |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Drug Radiosensitizer Radiobiology business.industry media_common.quotation_subject medicine.medical_treatment medicine.disease Clinical trial Radiation therapy 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Breast cancer Oncology In vivo 030220 oncology & carcinogenesis Disulfiram Cancer research medicine Pharmacology (medical) business media_common medicine.drug |
| Zdroj: | OncoTargets and Therapy. 13:10441-10446 |
| ISSN: | 1178-6930 |
| DOI: | 10.2147/ott.s271532 |
| Popis: | Disulfiram (DSF), also known as "Antabuse", has been widely used in clinical practice to treat alcoholism. In the past decades, both in vivo and in vitro experiments showed that DSF has strong anti-cancer activity, there were some clinical studies indicated the administration of this drug was associated with favorable survival in breast cancer. It is also evident that DSF has a radioprotective effect on normal cells and could be utilized during the course of radiation therapy. Moreover, increasing evidences demonstrated the role of DSF in enhancing the radiosensitivity of tumor cells in number of alternative mechanisms. Recent studies have also elaborated the anticancer mechanism of DSF in tumor cells. This review summarizes the anticancer activity of DSF both in preclinical studies and clinical trials, focuses on the advances of this drug in radiobiology and the treatment of breast cancer, and reveals the promising of repurposing DSF as a novel radiosensitizer and radioprotector in further clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |